Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma
Status:
Suspended
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the correct dose and safety of adding a new cancer
drug, Venetoclax, to a standard combination of chemotherapy drugs used prior to Autologous
stem cell transplant (ASCT) in participants with Non-Hodgkin Lymphoma (NHL). In this study,
Venetoclax will be added to BEAM (BCNU or carmustine, etoposide, cytarabine or ara-c, and
melphalan). All NHL participants are admitted for conditioning chemotherapy which is given
prior to the infusion of stem cells.
Venetoclax is a new anti-cancer drug that works by targeting a protein (known as the Bcl-2
protein). By inhibiting or "blocking" this protein, a downstream cascade occurs which results
in cancer cells to die. Adding Venetoclax to the standard BEAM conditioning chemotherapy with
autologous stem cell transplant is believed to increase the chance of remission. Venetoclax
is Food and Drug Administration (FDA) approved for participants with chronic lymphocytic
leukemia (CLL). However, Venetoclax is investigational for this study because it is not yet
approved for use in participants with NHL or in combination with BEAM chemotherapy.